Wolfe Research initiated coverage of Amgen (AMGN) with a Peer Perform rating.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen’s Uplizna shows potential efficacy in rare inflammatory diseases
- Amgen call volume above normal and directionally bullish
- American upgraded, Regeneron initiated: Wall Street’s top analyst calls
- Amgen initiated with a Neutral at Citi
- Amgen (NASDAQ:AMGN) Stock Rises Again on Bone Density Data Leak